As a leader in the emerging cellular therapy industry, NeoStem is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat, cure, or regenerate damaged or aged tissue, cells and organs and restoring their normal function.
Cellular therapy is the process by which new cells are introduced into a tissue to prevent or treat disease, or to regenerate damaged or aged tissue. Cellular therapy comprises a separate medical technology platform in addition to the current three pillars of healthcare: pharmaceuticals, biologics and medical devices. We believe that cell therapy will play a large role in changing the natural history of diseases as more breakthrough therapies are developed, ultimately lessening the overall burden of disease on patients and their families, as well as the economic burden that these diseases impose upon modern society.
Our business includes the development of novel proprietary cell therapy products as well a revenue generating contract development and manufacturing organization service business.
- NeoStem has an ambitious clinical development program that includes a diversified pipeline of therapeutics in different phases of development. Our clinical programs focus on Oncology (our Targeted Immunotherapy Program)*; Ischemic Repair (our CD34 Cell Program); Immune Modulation (our T Regulatory Cell Program) and Tissue Regeneration (our VSELTM Technology platform).
- Progenitor Cell Therapy, LLC (PCT), our wholly owned subsidiary, is an internationally recognized contract development and manufacturing organization that we not only leverage for the development of our therapeutics, but believe will benefit from the growth of the regenerative medicine industry.
- We have brought together a team of experienced and dedicated medical, scientific and business leaders, each with a proven track record of success in the sector.
These factors make NeoStem stand out as a leader in the rapidly growing cell therapy industry.
Thank you for visiting the NeoStem website and please read on to learn more.
Robin L. Smith, M.D., MBA
Chairman & CEO
*Program subject to closing of acquisition of California Stem Cell, Inc.